Unique clinical courses of transfusion-transmitted hepatitis E in patients with immunosuppression

Masahiro Satake, Keiji Matsubayashi, Yuji Hoshi, Rikizo Taira, Yasumi Furui, Norihiro Kokudo, Nobuhisa Akamatsu, Tomoharu Yoshizumi, Nobuhiro Ohkohchi, Hiroaki Okamoto, Masato Miyoshi, Akinori Tamura, Kyoko Fuse, Kenji Tadokoro

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

BACKGROUND: The high prevalence of specific immunoglobulin G for hepatitis E virus (HEV) in Japanese people raises the possibility of a high incidence of HEV-viremic blood donors and therefore frequent transfusion-transmitted HEV (TT-HEV). STUDY DESIGN AND METHODS: TT-HEV cases established in Japan through hemovigilance and those published in the literature were collected. Infectivity of HEV-contaminated blood components and disease severity in relation to immunosuppression were investigated. RESULTS: Twenty established TT-HEV cases were recorded over the past 17 years. A lookback study verified that five of 10 patients transfused with known HEV-contaminated blood components acquired HEV infection. The minimal infectious dose of HEV through transfusion was 3.6 × 104 IU. Nine of the 19 TT-HEV cases analyzed had hematologic diseases. Only two cases showed the maximal alanine aminotransferase level of more than 1000 U/L. Two patients with hematologic malignancy and two liver transplant recipients had chronic liver injury of moderate severity. CONCLUSION: The infectivity of HEV-contaminated components was 50%. Immunosuppression likely causes the moderate illness of TT-HEV, but it may lead to the establishment of chronic sequelae. Transfusion recipients, a population that is variably immunosuppressed, are more vulnerable to chronic liver injury as a result of TT-HEV than the general population is as a result of food-borne infection.

Original languageEnglish
Pages (from-to)280-288
Number of pages9
JournalTransfusion
Volume57
Issue number2
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Hepatitis E
Hepatitis E virus
Immunosuppression
Hematologic Diseases
Liver
Torque teno virus
Blood Safety
Viral Structures
Hepatitis A
Wounds and Injuries
Virus Diseases
Hematologic Neoplasms
Blood Donors
Alanine Transaminase
Population
Japan
Immunoglobulin G
Food
Incidence

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Hematology

Cite this

Satake, M., Matsubayashi, K., Hoshi, Y., Taira, R., Furui, Y., Kokudo, N., ... Tadokoro, K. (2017). Unique clinical courses of transfusion-transmitted hepatitis E in patients with immunosuppression. Transfusion, 57(2), 280-288. https://doi.org/10.1111/trf.13994

Unique clinical courses of transfusion-transmitted hepatitis E in patients with immunosuppression. / Satake, Masahiro; Matsubayashi, Keiji; Hoshi, Yuji; Taira, Rikizo; Furui, Yasumi; Kokudo, Norihiro; Akamatsu, Nobuhisa; Yoshizumi, Tomoharu; Ohkohchi, Nobuhiro; Okamoto, Hiroaki; Miyoshi, Masato; Tamura, Akinori; Fuse, Kyoko; Tadokoro, Kenji.

In: Transfusion, Vol. 57, No. 2, 01.02.2017, p. 280-288.

Research output: Contribution to journalArticle

Satake, M, Matsubayashi, K, Hoshi, Y, Taira, R, Furui, Y, Kokudo, N, Akamatsu, N, Yoshizumi, T, Ohkohchi, N, Okamoto, H, Miyoshi, M, Tamura, A, Fuse, K & Tadokoro, K 2017, 'Unique clinical courses of transfusion-transmitted hepatitis E in patients with immunosuppression', Transfusion, vol. 57, no. 2, pp. 280-288. https://doi.org/10.1111/trf.13994
Satake M, Matsubayashi K, Hoshi Y, Taira R, Furui Y, Kokudo N et al. Unique clinical courses of transfusion-transmitted hepatitis E in patients with immunosuppression. Transfusion. 2017 Feb 1;57(2):280-288. https://doi.org/10.1111/trf.13994
Satake, Masahiro ; Matsubayashi, Keiji ; Hoshi, Yuji ; Taira, Rikizo ; Furui, Yasumi ; Kokudo, Norihiro ; Akamatsu, Nobuhisa ; Yoshizumi, Tomoharu ; Ohkohchi, Nobuhiro ; Okamoto, Hiroaki ; Miyoshi, Masato ; Tamura, Akinori ; Fuse, Kyoko ; Tadokoro, Kenji. / Unique clinical courses of transfusion-transmitted hepatitis E in patients with immunosuppression. In: Transfusion. 2017 ; Vol. 57, No. 2. pp. 280-288.
@article{0af47c6ae1384eafbcce8755246616b2,
title = "Unique clinical courses of transfusion-transmitted hepatitis E in patients with immunosuppression",
abstract = "BACKGROUND: The high prevalence of specific immunoglobulin G for hepatitis E virus (HEV) in Japanese people raises the possibility of a high incidence of HEV-viremic blood donors and therefore frequent transfusion-transmitted HEV (TT-HEV). STUDY DESIGN AND METHODS: TT-HEV cases established in Japan through hemovigilance and those published in the literature were collected. Infectivity of HEV-contaminated blood components and disease severity in relation to immunosuppression were investigated. RESULTS: Twenty established TT-HEV cases were recorded over the past 17 years. A lookback study verified that five of 10 patients transfused with known HEV-contaminated blood components acquired HEV infection. The minimal infectious dose of HEV through transfusion was 3.6 × 104 IU. Nine of the 19 TT-HEV cases analyzed had hematologic diseases. Only two cases showed the maximal alanine aminotransferase level of more than 1000 U/L. Two patients with hematologic malignancy and two liver transplant recipients had chronic liver injury of moderate severity. CONCLUSION: The infectivity of HEV-contaminated components was 50{\%}. Immunosuppression likely causes the moderate illness of TT-HEV, but it may lead to the establishment of chronic sequelae. Transfusion recipients, a population that is variably immunosuppressed, are more vulnerable to chronic liver injury as a result of TT-HEV than the general population is as a result of food-borne infection.",
author = "Masahiro Satake and Keiji Matsubayashi and Yuji Hoshi and Rikizo Taira and Yasumi Furui and Norihiro Kokudo and Nobuhisa Akamatsu and Tomoharu Yoshizumi and Nobuhiro Ohkohchi and Hiroaki Okamoto and Masato Miyoshi and Akinori Tamura and Kyoko Fuse and Kenji Tadokoro",
year = "2017",
month = "2",
day = "1",
doi = "10.1111/trf.13994",
language = "English",
volume = "57",
pages = "280--288",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Unique clinical courses of transfusion-transmitted hepatitis E in patients with immunosuppression

AU - Satake, Masahiro

AU - Matsubayashi, Keiji

AU - Hoshi, Yuji

AU - Taira, Rikizo

AU - Furui, Yasumi

AU - Kokudo, Norihiro

AU - Akamatsu, Nobuhisa

AU - Yoshizumi, Tomoharu

AU - Ohkohchi, Nobuhiro

AU - Okamoto, Hiroaki

AU - Miyoshi, Masato

AU - Tamura, Akinori

AU - Fuse, Kyoko

AU - Tadokoro, Kenji

PY - 2017/2/1

Y1 - 2017/2/1

N2 - BACKGROUND: The high prevalence of specific immunoglobulin G for hepatitis E virus (HEV) in Japanese people raises the possibility of a high incidence of HEV-viremic blood donors and therefore frequent transfusion-transmitted HEV (TT-HEV). STUDY DESIGN AND METHODS: TT-HEV cases established in Japan through hemovigilance and those published in the literature were collected. Infectivity of HEV-contaminated blood components and disease severity in relation to immunosuppression were investigated. RESULTS: Twenty established TT-HEV cases were recorded over the past 17 years. A lookback study verified that five of 10 patients transfused with known HEV-contaminated blood components acquired HEV infection. The minimal infectious dose of HEV through transfusion was 3.6 × 104 IU. Nine of the 19 TT-HEV cases analyzed had hematologic diseases. Only two cases showed the maximal alanine aminotransferase level of more than 1000 U/L. Two patients with hematologic malignancy and two liver transplant recipients had chronic liver injury of moderate severity. CONCLUSION: The infectivity of HEV-contaminated components was 50%. Immunosuppression likely causes the moderate illness of TT-HEV, but it may lead to the establishment of chronic sequelae. Transfusion recipients, a population that is variably immunosuppressed, are more vulnerable to chronic liver injury as a result of TT-HEV than the general population is as a result of food-borne infection.

AB - BACKGROUND: The high prevalence of specific immunoglobulin G for hepatitis E virus (HEV) in Japanese people raises the possibility of a high incidence of HEV-viremic blood donors and therefore frequent transfusion-transmitted HEV (TT-HEV). STUDY DESIGN AND METHODS: TT-HEV cases established in Japan through hemovigilance and those published in the literature were collected. Infectivity of HEV-contaminated blood components and disease severity in relation to immunosuppression were investigated. RESULTS: Twenty established TT-HEV cases were recorded over the past 17 years. A lookback study verified that five of 10 patients transfused with known HEV-contaminated blood components acquired HEV infection. The minimal infectious dose of HEV through transfusion was 3.6 × 104 IU. Nine of the 19 TT-HEV cases analyzed had hematologic diseases. Only two cases showed the maximal alanine aminotransferase level of more than 1000 U/L. Two patients with hematologic malignancy and two liver transplant recipients had chronic liver injury of moderate severity. CONCLUSION: The infectivity of HEV-contaminated components was 50%. Immunosuppression likely causes the moderate illness of TT-HEV, but it may lead to the establishment of chronic sequelae. Transfusion recipients, a population that is variably immunosuppressed, are more vulnerable to chronic liver injury as a result of TT-HEV than the general population is as a result of food-borne infection.

UR - http://www.scopus.com/inward/record.url?scp=85011708624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011708624&partnerID=8YFLogxK

U2 - 10.1111/trf.13994

DO - 10.1111/trf.13994

M3 - Article

C2 - 28144952

AN - SCOPUS:85011708624

VL - 57

SP - 280

EP - 288

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 2

ER -